ANDA 76859, held by Chartwell RX. Amlodipine Besylate.
As of Nov 21, 2026, ANDA 76859 (Amlodipine Besylate), held by Chartwell RX, was first approved by FDA on Sep 10, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2007 | Original application | Approved | None posted |
| Amlodipine BesylateEQ 2.5MG BASE · tablet;oral | Amlodipine Besylate | Discontinued |
| Amlodipine BesylateEQ 5MG BASE · tablet;oral | Amlodipine Besylate | Discontinued |
| Amlodipine BesylateEQ 10MG BASE · tablet;oral | Amlodipine Besylate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters